Mammalian target of rapamycin inhibitors, an important therapeutic target for RCC, permits protein translation that drives cell growth, proliferation, and the production of angiogenic growth factors including HIF-1, VEGF, and PDGF. The gene discussed is VEGFA; the disease is renal cell carcinoma.